Treatment windows for ischemic stroke are expanding as medical understanding of tissue salvage improves, potentially helping thousands more patients avoid permanent disability. The timing of intervention has traditionally been the critical factor separating recovery from lifelong impairment. The American Stroke Association has issued updated clinical guidelines that broaden eligibility criteria for endovascular thrombectomy and tissue plasminogen activator therapy in adults while establishing evidence-based protocols for pediatric stroke management. Key changes include extending treatment timeframes beyond the previous rigid windows, incorporating advanced imaging to identify salvageable brain tissue, and recognizing that stroke response varies significantly by age and presentation. For pediatric cases, the guidelines address a previously neglected area where treatment decisions often relied on adult extrapolations rather than age-specific evidence. The expanded adult criteria particularly benefit patients who present outside traditional time windows but show imaging evidence of recoverable tissue. These modifications reflect a paradigm shift from time-based to tissue-based treatment decisions, leveraging perfusion imaging and collateral circulation assessments. However, implementation requires sophisticated imaging infrastructure and specialized expertise that may not be universally available. The pediatric recommendations, while groundbreaking, are necessarily based on limited clinical trial data given the rarity of childhood stroke. The guidelines represent incremental but meaningful progress in stroke care, potentially improving outcomes for both demographics while highlighting persistent gaps in pediatric research and healthcare accessibility.